The Company's shareholder's resolution to discharge
the director's non-compete clause
Date of events
2022/05/24
To which item it meets
paragraph 21
Statement
1.Date of the shareholders' meeting resolution:2022/05/24
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
Sheng Pao-Shi, chairman of Bora Pharmaceuticals
3.Items of competitive conduct in which the officer is
permitted to engage:Same business scope as the company
4.Period of permission to engage in the competitive conduct:
During the term for the board of director
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):In accordance with Article 209 of the Company
Act, the Company's shareholder has resolved to discharege
the director's non-compete clause on 2022/05/24.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):NA
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:NA
8.Address of the mainland China enterprise:NA
9.Operations of the mainland China enterprise:NA
10.Impact on the company's finance and business:NA
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:NA
12.Any other matters that need to be specified:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 24 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2022 03:57:01 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
